Physician profile
Daniel Lee
NPI 1104876093
$166,910.41
in general payments reported to CMS, 2019-2025
15 companies · $33K in 2025
The $33K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $12K · 2021: $2,089 · 2022: $23K · 2023: $22K · 2024: $32K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $49K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $5,634 · Travel and Lodging: $4,032 · Honoraria: $3,960 · Education: $64.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $48,910.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,272.50 |
| Food and Beverage | $5,634.27 |
| Travel and Lodging | $4,032.08 |
| Honoraria | $3,960.00 |
| Education | $64.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $73,845.14 | 2019-2025 | Serostim, Serostim |
| Theratechnologies INC. | $47,009.92 | 2019-2025 | Egrifta, Trogarzo, Egrifta Sv |
| Viiv Healthcare Company | $30,794.00 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Merck Sharp & Dohme LLC | $8,423.51 | 2019-2025 | |
| Gilead Sciences, INC. | $4,379.39 | 2020-2025 | Biktarvy |
| Glaxosmithkline, LLC. | $942.75 | 2019 | |
| Janssen Biotech, INC. | $664.50 | 2019-2025 | Simponi, Tremfya, Stelara |
| Janssen Products, LP | $500.00 | 2020 | |
| Lilly USA, LLC | $163.36 | 2021-2025 | Zepbound |
| Janssen Scientific Affairs, LLC | $49.79 | 2023 | Symtuza |
| Acadia Pharmaceuticals INC | $41.78 | 2023-2025 | Nuplazid |
| Mis Implants Technologies, INC. | $35.08 | 2019 | |
| Cequr Corporation | $25.38 | 2024-2025 | Cequr Simplicity |
| Regeneron Healthcare Solutions, INC. | $18.99 | 2023 | Evkeeza |
| Sunovion Pharmaceuticals INC. | $16.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.